Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASCO Annual Meeting Coverage

Set Alert for ASCO Coverage

The American Society of Clinical Oncology annual meeting for 2023 takes place in Chicago from 2-6 June. This page is your one-stop shop for all of Scrip's conference coverage, including preview and post-meeting analysis. You can also find archive content from previous meetings here.

Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data

The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.

ASCO Interviews

Chinese Language Podcast: ASCO专集

J&J and Legend’s Carvykti shines at ASCO while Junshi provides PD-1 antibody toripalimab updates. Alongside, ADCs from Biokin, BlissBio also steps into the spotlight. Guest speaker Leon Tang in the US, Brian Yang in Beijing and Dexter Yan in Shanghai discuss what stands out in this special ASCO episode of the latest Chinese-language podcast. 

China Clinical Trials

Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy

The PD-1/LAG-3 combination showed a high response rate in a small number of melanoma patients with prior PD-1 exposure.

ASCO Interviews

Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy

The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.

ASCO ImmunoOncology

Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO

Regeneron presented data for linvoseltamab, while Pfizer presented data for elranatamab, including in patients who previously received BCMA-directed therapy. 

ASCO Clinical Trials

ASCO 2023 – Novartis’s Adjuvant Breast Cancer Win Comes With Caveats

The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.

ASCO Clinical Trials

ASCO 2023 – Roche Sees Morpheus And Takes The Red Pill

The company’s TIGIT data are strong enough for a phase 3 trial to be launched, ASCO learns.

ASCO Clinical Trials

ASCO 2023 – Bicara Eyes Head And Neck Niche

Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.

ASCO Clinical Trials

ADAURA Survival Boost For AZ’s Tagrisso

Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.

ASCO Clinical Trials
See All
UsernamePublicRestriction

Register